You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 3
  • 36 Prognostic value and association with veliparib benefit of modeled CA-125 elimination kinetics (KELIM) in patients with newly diagnosed ovarian cancer: analysis from the VELIA/GOG-3005 study

Article info

Article menu

Download PDFPDF

Oral Poster – TAPED
Oral Featured Posters – Pre-Recorded
IGCS20_1102
36 Prognostic value and association with veliparib benefit of modeled CA-125 elimination kinetics (KELIM) in patients with newly diagnosed ovarian cancer: analysis from the VELIA/GOG-3005 study
Free

Authors

Citation

You B, Fleming G, Bookman M, et al
36 Prognostic value and association with veliparib benefit of modeled CA-125 elimination kinetics (KELIM) in patients with newly diagnosed ovarian cancer: analysis from the VELIA/GOG-3005 study
International Journal of Gynecologic Cancer 2020;30:A24-A25.

Publication history

  • First published November 13, 2020.
Online issue publication 
November 13, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.